文献リスト

1) Högenauer CH, Langner C, Beubler E, et al. Klebsiella oxytoca as a causative organism of antibiotic-associated hemorrhagic colitis. N Engl J Med. 2006; 355: 2418-26

2) わが国における腸炎由来 Campylobacter jejuniの血清型別検出動向およびキノロン剤に対する耐性菌の出現状況, 2005年～2008年-カンピロバクターレファレンスセンター. IASR. 2010; 31: 15-7

3) Pope JE, Krizova A, Garg AX, et al. Campylobacter reactive arthritis: a systematic review. Semin Arthritis Rheum. 2007; 37: 48-55

4) Lecuit M, Abachin E, Martin A, et al. Immunoproliferative small intestinal disease associated with Campylobacter jejuni. N Engl J Med. 2004; 350: 239-48

5) Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet. 2005; 366: 1653-66

6) Koga M, Gilbert M, Takahashi M, et al. Comprehensive analysis of bacterial risk facters for the development of Guillain-Barré syndrome after Campylobacter jejuni enteritis. J Inf Dis. 2006; 193: 547-55

7) Spiller RC. Role of infection in irritable bowel syndrome. J Gastroenterol. 2007; 42: 41-7

8) DuPont AW. Postinfectious irritable bowel syndrome. Clin Inf Dis. 2008; 46: 594-9

9) Temhag A, Asikainen T, Giesecke J, et al. A meta-analysis on the effects of antibiotic treatment on duration of symptoms caused by infection with Campylobacter species. Clin Infect Dis. 2007; 44: 696-700

10) Marshall JK, Thabana M, Garg AX, et al. Eight year prognosis of postinfectious irritable bowel syndrome following bacterial dysentery. Gut. 2010; 59: 605-11

11) Kalischuk LD, Buret AG. A role for Campylobacter jejuni-induced enteritis in inflammatory bowel disease？ Am J Physiol Gastrointest Liver Physiol. 2009; 298: G1-G9

12) Gradel KO, Nielsen HL, Schønheyder HC, et al. Increased short- and long term risk of inflammatory bowel disease after Salmonella or Campylobacter gastroenteritis. Gastroenterology. 2009; 137: 495-501

13) Doorduyn Y, Van Pelt W, Siezen CL, et al. Novel insight in the association between salmonellosis or campylobacteriosis and chronic illness, and the role of host genetics in susceptibility to these diseases. Epidemiol Infect. 2008; 136: 1225-34

14) Sobieszczańska BM, Osek J, Waśko-Czopnik D, et al. Association of enteroaggregative Escherichisa coli with irritable bowel syndrome. Clin Microbiol Infect. 2007; 13: 404-7

15) Johnson KE, Thorpe CM, Sears CL. The emereging clinical importance of non-O157 Shiga toxin-producing Escherichia coli. Clin Infect Dis. 2006; 43: 1587-95

16) 腸管出血性大腸菌感染症. 2011年4月現在. IASR. 2010; 32: 125-6

17) Characteristics of the enteroaggregative Shiga toxin/verotoxin-producing Escherichia coli O104: H4 strain causing the outbreak of hemolytic uremic syndrome in Germany, May to June 2011. Eurosurveillance. 2011; 16: 24

18) Frank C, Weber D, Cramer JP, et al. Epidemic profile of Shiga-toxin-producing Escherichia coli O104: H4 outbreak in Germany – preliminary report. N Engl J Med. 2011; 365: 1771-80

19) Bielaszewska M, Mellmann A, Zhang W, et al. Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uremic syndrome in Germany, 2011: a microbiological study. Lancet Infect Dis. 2011; 11: 671-6. Epub 2011 Jun 22

20) Brzuskiewics E, Thürmer A, Schuldes J, et al. Genome sequence analysis of two isolates from the recent Escherichia coli outbreak in Germany reveal the emergency of a new pathotype: Entero-aggregative-hemorrhagic Escherichia coli (EAHEC). Arch Microbiol. 2011 Jun29. [Epub ahead of print]

21) Rodriguez-Palacios A, Reid-Smith RJ, Staempfli HR, et al. Clostridium difficile in retail ground meat, Canada. Emerg Inf Dis. 2007; 13: 485-7

22) McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005; 353: 2433-41

23) Killgore G, Thompson A, Johnson S, et al. Comparison of seven techniques for typing international epidemic strains of Clostridium difficile. restriction endonuclease analysis, pulsed-field gel electrophoresis, PCR-ribotyping, multilocus sequence typing, multilocus variable number tandem-repeat analysis, amplified fragment length polymorphism, and surface layer protein A gene sequence typing. J Clin Microbiol. 2008; 46: 431-7

24) Iwashita Y, Nakamura A, Kato H, et al. A retrospective study of the epidemiology of Clostridium difficile infection at a University Hospital in Japan: genotypic features of the isolates and clinical characteristics of the patients. J Inf Chemother. 2010; 16: 329-33

25) Tonna I, Welsby PD. Pathogenesis and treatment of Clostridium difficile infection. Postgrad Med J. 2005; 81: 367-79

26) Zar FA, Bakkanagari SR, Moorthi KM, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis. 2007; 45: 302-7

27) Cohen SH. Clinical practice guideline for Clostridium difficile infection in adults. 2010 update by the Society for Healthcare Epidemiology of America(SHEA) and the Infectious Disease Society of America(IDSA). Infect Control Hospital Epidemiol. 2010; 31: 431-55

28) Kelly CP, LaMont JT. Clostridium difficile– more difficult than ever. N Engl J Med. 2008; 359: 1932-40

29) Abougergi MS, Broor A, Cui W, et al. Intravenous immunoglobulin for the treatment of severe Clostridium difficile colitis: an observational study and review of the literature. J Hosp Med. 2010; 5: e1-9

30) Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med. 2010; 362: 197-205

31) Bakken JS. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe. 2009; 15: 285-9

32) Grehan MJ, Borody TJ, Leis SM, et al. Durable alteration of the colonic microbiota by the administration of donor fecal flora. J Clin Gastroenterol. 2010; 44: 551-61

33) Lee BY, Popovich MJ, Tian Y, et al. The potential value of Clostridium difficile vaccine: an economic computer simulation model. Vaccine. 2010; 28: 5245-53

34) Gao XW, Mubasher M, Fang CY, et al. Dose-response efficacy of a proprietary probiotic formula of Lactobacillus acidophilus CL1285 and Lactobacillus casei LBC80R for antibiotic-associated diarrhea and Clostridium difficile-associated diarrhea prophylaxis in adult patients. Am J Gastroenterol. 2010; 105: 1636-41

35) Rodemann JF, Dubberke ER, Reske KA, et al. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2007; 5: 339-44

36) Issa M, Ananthakrishnan AN, Binion DG. Clostridium difficile and inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14: 1432-42

37) Ananthakrishnan AN, McGinley EL, Binion DG. Excess hospitalization burden associated with Clostridium diffcile in patients with inflammatory bowel disease. Gut. 2008; 57: 205-10

38) Schneeweiss S, Korzenik J, Solomon DH, et al. Infliximab and other immunomodulating drugs in patients with inflammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ther. 2009; 30: 253-64

39) Bossuyt P, Verhaegen J, Van Assche G, et al. Increasing incidence of Clostridium difficile-associated diarrhea in inflammatory bowel disease. J Crohns Colitis. 2009; 3: 4-7

40) Shen B, Jiang ZD, Fazio VW, et al. Clostridium difficile infection in patients with ileal pouch-anal anastomosis. Clin Gastroenterol and Hepatol. 2008; 6: 782-8

41) Causey MW, Spencer MP, Steele SR. Clostridium difficile enteritis after colectomy. Am Surg. 2009; 75: 1203-6

42) Lundeen SJ, Otterson MF, Binion DG, et al. Clostridium difficile enteritis: an early postoperative complication in inflammatory bowel disease patients after colectomy. J Gastrointest Surg. 2007; 11: 138-42

43) Glass RI, Parasher UD, Estes MK. Norovirus gastroenteritis. N Engl J Med. 2009; 361: 1771-85

44) Siebenga JJ, Vennema H, Zheng DP, et al. Norovirus illness is a global problem: emergence and apread of norovirus GⅡ. 4 variants, 2001-2007. J Infect Dis. 2009; 200: 802-12

45) ノロウィルスの流行2006/07～2009/10シーズン. IASR. 2010; 31: 312-4

46) Tuan Zainazor C, Hidayah MS, Chai LC, et al. The scenario of norovirus contamination in food and food handlers. J Microbiol Biotechnol. 2010; 20: 229-37

47) Teunis PF, Moe CL, Liu P, et al. Norwalk virus: how infectious is it？ J Med Virol. 2008; 80: 1468-76

48) Atmar RL, Opekun AR, Gilger MA, et al. Norwalk virus shedding after experimental human infection. Emerg Infect Dis. 2008; 14: 1553-7

49) Ozawa K, Oka T, Takada N, et al. Norovirus infection in symptomatic and asymptomatic food handlers in Japan. J Clin Microbiol. 2007; 45: 3996-4005

50) Phillips G, Tam CC, Rodrigues LC, et al. Prevalence and characteristics of asymptomatic norovirus infection in the community in England. Epidemiol Infect. 2010; 138: 1454-8

51) Koo HL, DuPont HL. Noroviruses as a potential cause of protracted and lethal disease in immunocompromized patients. Clin Infect Dis. 2009; 49: 1069-71

52) Turcios-Ruis RM, Axelrod P, John KS, et al. Outbreak of necrotizing enterocolitis caused by norovirus ina neonatal intensive care unit. J Pediatr. 2008; 153: 339-44

53) Chen SY, Tsai CN, Lai MW, et al. Norovirus infection as a cause of diarrhea-associated benign infantile seizures. Clin Infect Dis. 2009; 48: 849-55

54) Khan RR, Lawson AD, Minnich LL, et al. Gastrointestinal norovirus infection associated with exacerbation of inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2009; 48: 328-33

55) Matsuoka K, Iwao Y, Mori T, et al. Cytomegalovirus is frequently reactivated and disappears without antiviral agents in ulcerative colitis patients. Am J Gastroenterol. 2007; 102: 331-7

56) Suzuki H, Kato J, Kuriyama M, et al. Specific endoscopic features of ulcerative colitis complicated by cytomegalovirus infection. World J Gastroenterol. 2010; 16: 1245-51

57) Yoshino T, Nakase H, Ueno S, et al. Usefulness of quantitative real-time PCR assay for early detection of cytomegalovirus infection in patients with ulcerative colitis refractory to immunosuppressive therapies. Inflamm Bowel Dis. 2007; 13: 1516-21

58) Hans HH, Long MD, Rubinas TC, et al. Evaluation of a non-invasive method to detect cytomegalovirus(CMV)-DNA in stool samples of patients with inflammatory bowel disease(IBD): a pilot study. Dig Dis Sci. 2010; 55: 1053-8

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp